Xeris Pharmaceuticals, Inc.

CHICAGO--(BUSINESS WIRE)--Dec. 1, 2025-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its subsidiary Xeris Pharmaceuticals Inc.’s U.S. patent application covering XP-8121, one of its novel product candidates. The Notice of Allowance indicates that the USPTO has determined the application meets the requirements for patentability and is expected to issue as a U.S. patent following standard administrative steps. The allowed claims in this application are specific to the XP-8121 formulation. In parallel, Xeris continues to pursue additional layers of U.S. and international IP protection in the levothyroxine (LT4) technology space. “We believe XP-8121 has tremendous potential to solve an unmet medical need for hypothyroidism, and this patent represents a key milestone in strengthening our intellectual property protection around this important pipeline program,” said John Shannon, Chief Executive Officer. “It further demonstrates the ability of our XeriSol® platform to enable the development of difficult-to-formulate drugs into subcutaneous injections.” About XP-8121 XP-8121 is an investigational, ready-to-use liquid formulation of levothyroxine sodium designed for once-weekly subcutaneous injection using Xeris’ proprietary XeriSol® technology. By avoiding the gastrointestinal tract, XP-8121 may address the well-documented limitations of oral levothyroxine, including variable absorption, drug and food interactions, and inconsistent therapeutic effect. About Xeris Xeris (Nasdaq: XERS) is a fast-growing biopharmaceutical Company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing’s syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, and a gastrointestinal motility inhibitor when used as a diagnostic aid; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as well as early-stage programs leveraging Xeris’ technology platforms, XeriSol® and XeriJect®, for its partners. Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on X, LinkedIn, or Instagram. Forward-Looking Statements Any statements in this press release other than statements of historical fact are forward-looking statements. Forward-looking statements include, but are not limited to, statements about future expectations, plans, opportunities, and prospects for Xeris Biopharma Holdings, Inc., including statements regarding the scope, timing and outcome of future regulatory actions, its pursuit of global protection of its intellectual property, the market and therapeutic potential of its products and product candidates, including XP-8121’s potential to solve an unmet medical need for hypothyroidism, the potential utility of its formulation platforms such as XeriSol®, the advancement of its pipeline, and other statements containing the words "achieve," "anticipate," "continue," “will,” “would,” “continue,” “expect,” “should,” “anticipate” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on numerous assumptions and assessments made in light of Xeris’ experience and perception of historical trends, current conditions, business strategies, operating environment, future developments, geopolitical factors and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The various factors that could cause Xeris’ actual results (including revenue and sales in the near- and long-term), performance or achievements, industry results, market opportunity and developments to differ materially from those expressed in or implied by such forward-looking statements, include, but are not limited to, its financial position and need for financing, including to fund its product development programs or commercialization efforts, whether its products will achieve and maintain market acceptance in a competitive business environment, its reliance on third-party suppliers, including single-source suppliers, its reliance on third parties to conduct clinical trials, the ability of its product candidates to compete successfully with existing and new drugs, its and collaborators’ ability to protect its intellectual property and proprietary technology, the accuracy and completeness of its assumptions and its ability to accurately estimate future financial results and market opportunities, and general macroeconomic and geopolitical conditions, including the possibility of an economic downturn, changes in governmental priorities and resources, announced or implemented tariffs or export controls and market volatility. No assurance can be given that such expectations will be realized and persons reading this communication are, therefore, cautioned not to place undue reliance on these forward-looking statements. Additional risks and information about potential impacts of financial, operational, economic, competitive, regulatory, governmental, technological, and other factors that may affect Xeris can be found in Xeris’ filings, including its most recently filed Annual Report on Form 10-K and subsequent filings with the U.S. Securities and Exchange Commission, the contents of which are not incorporated by reference into, nor do they form part of, this communication. The risks described herein and in Xeris’ U.S. Securities and Exchange Commission filings are not the only risks the Company faces. Additional risks and uncertainties not currently known to it or that it currently deems immaterial may also impact its business operations or financial results. Forward-looking statements in this communication are based on information available to management, as of the date of this communication and, while the Company believes its assumptions are reasonable, actual results may differ materially. Subject to any obligations under applicable law, the Company does not undertake any obligation to update any forward-looking statement whether as a result of new information, future developments or otherwise, or to conform any forward-looking statement to actual results, future events, or to changes in expectations. View source version on businesswire.com: https://www.businesswire.com/news/home/20251201785819/en/ Investor Contact Allison Wey Senior Vice President, Investor Relations and Corporate Communications awey@xerispharma.com Source: Xeris Biopharma Holdings, Inc.

Total product revenue increased 40% YoY to $74 million Recorlev® revenue grew 109% YoY to $37 million Updating full-year 2025 total revenue guidance to $285-$290 million ; previously $280-$290 million Hosts conference call and webcast today at 8:30 a.m. ET CHICAGO --(BUSINESS WIRE)--Nov. 6, 2025-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the third quarter ended September 30, 2025 . “We delivered another record-breaking quarter, driven by increased patient demand across all three products,” said John Shannon , Chief Executive Officer. “Total product revenue grew 40% year-over-year, highlighting the strength of our portfolio and the meaningful difference we’re making in the lives of patients and providers alike. Recorlev led the way, with revenue growing 109% to $37 million , further validating its significant growth potential." Shannon continued, "Our year-to-date performance underscores the strength of our growth engine and the effectiveness of our strategic execution. With momentum continuing to build across the business, we are updating our 2025 total revenue guidance to $285-$290 million , which implies 42% growth at the midpoint compared to last year. As we progress through the final quarter, our focus remains on executing and investing in opportunities that will propel sustained growth into 2026 and beyond." Third Quarter 2025 Highlights Three months ended September 30 , Change 2025 2024 $ % Product revenue (in thousands): Recorlev $ 36,975 $ 17,726 $ 19,249 108.6 Gvoke 25,151 22,942 2,209 9.6 Keveyis 11,937 12,193 (256 ) (2.1 ) Product revenue, net 74,063 52,861 21,202 40.1 Royalty, contract and other revenue 317 1,407 (1,090 ) (77.5 ) Total revenue $ 74,380 $ 54,268 $ 20,112 37.1 Recorlev® net revenue was $37.0 million – an increase of approximately 109% compared to the third quarter of 2024. This growth was due to increased patient demand. Gvoke® net revenue was $25.2 million – an increase of approximately 10% compared to the third quarter of 2024. The increase was due to higher volume and favorable net pricing. Keveyis® net revenue was $11.9 million – a decrease of approximately 2% compared to the third quarter of 2024. Cost of goods sold (COGS) decreased $2.6 million or 19% in the third quarter of 2025 compared to the same period last year. This improvement was primarily due to a reduction of Gvoke inventory write-offs in 2025. Research and development (R&D) expenses increased $1.6 million or 27% in the third quarter of 2025 compared to the same period last year. The increase in R&D expenses primarily reflects personnel-related expenses to support both XP-8121 and the ongoing development of the Company's technology platforms and partnerships. Selling, general and administrative (SG&A) expenses increased $1.5 million or 3% in the third quarter of 2025 compared to the same period last year. This increase mainly reflects incremental personnel related expenses. Net income for the third quarter was $0.6 million , compared to a net loss of $15.7 million in the same period last year. Adjusted EBITDA1 for the third quarter was $17.4 million , an improvement of $20.1 million compared to the third quarter of 2024. First Nine Months 2025 Highlights Nine months ended September 30 , Change 2025 2024 $ % Product revenue (in thousands): Recorlev $ 93,949 $ 41,663 $ 52,286 125.5 Gvoke 69,463 59,567 9,896 16.6 Keveyis 34,849 38,406 (3,557 ) (9.3 ) Other product revenue 1,312 — 1,312 — Product revenue, net 199,573 139,636 59,937 42.9 Royalty, contract and other revenue 6,465 3,335 3,130 93.9 Total revenue $ 206,038 $ 142,971 $ 63,067 44.1 Recorlev® net revenue was $94.0 million - an increase of approximately 126% compared to the nine months ended September 30, 2024 . This growth was due to increased patient demand. Gvoke® net revenue was $69.5 million - an increase of approximately 17% compared to the nine months ended September 30, 2024 . The increase was due to higher volume and favorable net pricing. Keveyis® net revenue was $34.9 million - a decrease of approximately 9% compared to the nine months ended September 30, 2024 . The decrease was due to unfavorable net pricing, partially offset by higher volume. Other product revenue increased by $1.3 million for the nine months ended September 30, 2025 . This includes the sale of Gvoke VialDx units to American Regent . Royalty, contract and other revenue was $6.5 million and primarily reflects the recognition of milestones for Gvoke VialDxTM. Cost of goods sold (COGS) increased $4.3 million or 16% for the nine months ended September 30, 2025 , compared to the same period in 2024. This increase was primarily due to an increase in product revenue. Research and development (R&D) expenses increased $3.8 million or 20% for the nine months ended September 30, 2025 , compared to the same period last year. The increase in R&D expenses primarily reflects personnel-related expenses to support both XP-8121 and ongoing development of the Company's technology platforms and partnerships. Selling, general and administrative (SG&A) expenses increased $11.5 million or 9% for the nine months ended September 30, 2025 compared to the same period last year. The increase mainly reflects higher personnel related expense ( $7.9 million ), largely due to investments made in the Recorlev commercial organization starting in the third quarter of 2024. Net loss for the nine months ending September 30, 2025 , was $10.5 million or ( $0.07 ) per share, compared to a net loss of $49.7 million or ( $0.34 ) per share in the prior year period. This represents a 79% improvement versus the prior year period. Adjusted EBITDA1 for the nine months ended September 30, 2025 was $34.3 million , an improvement of $41.4 million compared to the nine months ended September 30, 2024 . Total Shares Outstanding were 165,924,289 at October 31, 2025 . Upcoming Events Jefferies Global Healthcare Conference : Senior management will participate in 1x1 meetings on November 17-19, 2025 in London, UK . Please contact the sponsor to arrange meetings with management. Piper Sandler 37th Annual Healthcare Conference: Senior management will participate in 1x1 meetings and a fireside chat on December 2, 2025 in New York City , NY. Please contact the sponsor to arrange meetings with management. 1 Adjusted EBITDA is a non-GAAP financial measure. See "Note Regarding Use of Non-GAAP Financial Measures" and the corresponding financial tables at the end of this press release for definitions and reconciliations of non-GAAP measures. Conference Call and Webcast Details Xeris will host a conference call and webcast at 8:30 a.m. Eastern Time today to discuss the Company's financial and operational results. To pre-register for the conference call, please use the following link: https://www.netroadshow.com/events/login/LE9zwo3lV0p4Y9XVAt3dNbajZlK6unmUrMO After registering, a confirmation email will be sent, including dial-in details and a unique code for entry. The Company recommends registering a minimum of ten minutes prior to the start of the call. Following the conference call, a replay will be available until Thursday, November 20, 2025 , at US:1 929 458 6194, US Toll Free: 1 866 813 9403, UK : 0204 525 0658, Canada : 1 226 828 7578, or all other locations: +44 204 525 0658 Access Code: 606180. To join the webcast, please visit “Events” on investor relations page of the Company’s website at www.xerispharma.com or use this link: https://events.q4inc.com/attendee/310744356. Note Regarding Use of Non-GAAP Financial Measures This press release includes financial results prepared in accordance with generally accepted accounting principles in the United States (GAAP) and also certain historical and forward-looking non-GAAP financial measures, namely Adjusted EBITDA. This non-GAAP financial measure is not meant to be considered in isolation and should be read in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP, and was not prepared under any comprehensive set of accounting rules or principles. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP, and the calculation of the non-GAAP financial measure included herein may differ from similarly titled measures used by other companies. The Company believes that the presentation of Adjusted EBITDA, when viewed in conjunction with actual GAAP results, provides investors with a more meaningful understanding of the Company's ongoing and projected operating performance, exclusive of factors that do not directly affect what the Company considers to be its core operating performance, as well as unusual events. The Company believes this non-GAAP financial measure helps indicate underlying trends in the Company’s business and is important in comparing current results with prior period results and understanding expected operating performance. Also, management uses this non-GAAP financial measure to establish budgets and operational goals, and to manage the Company’s business and evaluate its performance. In addition, management believes that Adjusted EBITDA is important in evaluating the administrative costs of operating the Company’s business. Adjusted EBITDA is GAAP net income (loss) before income tax (benefit) expense, plus interest and other income, less depreciation and amortization, interest expenses, share based compensation and debt refinancing fees. About Xeris Xeris (Nasdaq: XERS) is a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing’s syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as well as multiple early-stage programs leveraging Xeris’ technology platforms, XeriSol® and XeriJect®, for its partners. Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on X, LinkedIn, or Instagram. Forward-Looking Statements Any statements in this press release other than statements of historical fact are forward-looking statements. Forward-looking statements include, but are not limited to, statements about future expectations, plans, opportunities, and prospects for Xeris Biopharma Holdings, Inc. , including statements regarding financial guidance for full-year 2025 revenue, statements regarding its ability to continue to generate net income, Recorlev’s growth potential, the ability to continue to demonstrate rapid revenue growth, the effectiveness of the Company’s strategic execution, the Company’s ability to continue on its current growth trajectory and continue to drive patient demand, advancing its strategic initiatives, its ability to create value, the ability to continue to demonstrate sustained momentum across the portfolio and the market and therapeutic potential of its products and product candidates, the potential utility of its formulation platforms, the advancement of its pipeline, and other statements containing the words "achieve," "anticipate," "continue," “will,” “would,” “continue,” “expect,” “should,” “anticipate” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on numerous assumptions and assessments made in light of Xeris’ experience and perception of historical trends, current conditions, business strategies, operating environment, future developments, geopolitical factors and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The various factors that could cause Xeris’ actual results (including revenue and sales in the near- and long-term), performance or achievements, industry results, market opportunity and developments to differ materially from those expressed in or implied by such forward-looking statements (including its 2025 guidance), include, but are not limited to, its financial position and need for financing, including to fund its product development programs or commercialization efforts, whether its products will achieve and maintain market acceptance in a competitive business environment, its reliance on third-party suppliers, including single-source suppliers, its reliance on third parties to conduct clinical trials, the ability of its product candidates to compete successfully with existing and new drugs, its and collaborators’ ability to protect its intellectual property and proprietary technology, the accuracy and completeness of its assumptions and its ability to accurately estimate future financial results and market opportunities, and general macroeconomic and geopolitical conditions, including the possibility of an economic downturn, changes in governmental priorities and resources, announced or implemented tariffs or export controls and market volatility. No assurance can be given that such expectations will be realized and persons reading this communication are, therefore, cautioned not to place undue reliance on these forward-looking statements. Additional risks and information about potential impacts of financial, operational, economic, competitive, regulatory, governmental, technological, and other factors that may affect Xeris can be found in Xeris’ filings, including its most recently filed Annual Report on Form 10-K and subsequent filings with the U.S. Securities and Exchange Commission, the contents of which are not incorporated by reference into, nor do they form part of, this communication. The risks described herein and in Xeris’ U.S. Securities and Exchange Commission filings are not the only risks the Company faces. Additional risks and uncertainties not currently known to it or that it currently deems immaterial may also impact its business operations or financial results. Forward-looking statements in this communication are based on information available to management, as of the date of this communication and, while the Company believes its assumptions are reasonable, actual results may differ materially. Subject to any obligations under applicable law, the Company does not undertake any obligation to update any forward-looking statement whether as a result of new information, future developments or otherwise, or to conform any forward-looking statement to actual results, future events, or to changes in expectations. XERIS BIOPHARMA HOLDINGS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share data, unaudited) Three Months Ended September 30 , Nine Months Ended September 30 , 2025 2024 2025 2024 Product revenue, net $ 74,063 $ 52,861 $ 199,573 $ 139,636 Royalty, contract and other revenue 317 1,407 6,465 3,335 Total revenue 74,380 54,268 206,038 142,971 Costs and expenses: Cost of goods sold 10,996 13,593 31,622 27,354 Research and development 7,483 5,888 23,291 19,468 Selling, general and administrative 46,459 44,969 134,870 123,342 Amortization of intangible assets 2,711 2,711 8,132 8,132 Total costs and expenses 67,649 67,161 197,915 178,296 Income (loss) from operations 6,731 (12,893 ) 8,123 (35,325 ) Other expenses (6,110 ) (6,169 ) (18,650 ) (16,666 ) Net income (loss) before benefit from income taxes 621 (19,062 ) (10,527 ) (51,991 ) Income tax benefit — 3,324 — 2,268 Net income (loss) $ 621 $ (15,738 ) $ (10,527 ) $ (49,723 ) Net income (loss) per common share - basic $ 0.00 $ (0.11 ) $ (0.07 ) $ (0.34 ) Net income (loss) per common share - diluted $ 0.00 $ (0.11 ) $ (0.07 ) $ (0.34 ) Weighted average common shares outstanding Basic 163,649,932 148,993,823 158,559,467 145,962,198 Diluted 177,617,307 148,993,823 158,559,467 145,962,198 XERIS BIOPHARMA HOLDINGS, INC. Non-GAAP Financial Measures - EBITDA and Adjusted EBITDA (in thousands, unaudited) Three Months Ended September 30 , Nine Months Ended September 30 , 2025 2024 2025 2024 GAAP Net income (loss) $ 621 $ (15,738 ) $ (10,527 ) $ (49,723 ) Adjustments Interest and other income (1,158 ) (1,197 ) (3,281 ) (4,411 ) Interest expense 7,268 7,786 21,931 22,782 Income tax benefit — (3,324 ) — (2,268 ) Depreciation and amortization 3,049 3,018 9,110 9,046 EBITDA $ 9,780 $ (9,455 ) $ 17,233 $ (24,574 ) Adjustments Share-based compensation (a) 7,642 6,768 17,094 14,768 Debt refinancing fees (b) — — — 2,690 Adjusted EBITDA $ 17,422 $ (2,687 ) $ 34,327 $ (7,116 ) (a) Includes non-cash, stock-based compensation, net of forfeitures. (b) Represents non-recurring fees related to financing activities. Including debt refinancing fees which related to advisory and legal fees to refinance the term loan in 2024. XERIS BIOPHARMA HOLDINGS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) September 30, 2025 December 31, 2024 (unaudited) Assets Current assets: Cash and cash equivalents $ 91,598 $ 71,621 Trade accounts receivable, net 53,751 40,415 Inventory, net 67,462 48,175 Prepaid expenses and other current assets 11,206 7,451 Total current assets 224,017 167,662 Property and equipment, net 4,946 5,562 Operating lease right-of-use assets 22,263 22,649 Goodwill 22,859 22,859 Intangible assets, net 90,789 98,921 Other assets 5,317 5,407 Total assets $ 370,191 $ 323,060 Liabilities and Stockholders’ Equity (deficit) Current liabilities: Accounts payable $ 6,527 $ 2,290 Current portion of long-term debt — 15,102 Current operating lease liabilities 6,194 6,080 Other accrued liabilities 30,350 27,716 Accrued trade discounts and rebates 51,264 29,084 Accrued returns reserve 19,216 19,082 Other current liabilities 2,649 1,089 Total current liabilities 116,200 100,443 Long-term debt, net of unamortized debt issuance costs 219,469 217,006 Non-current operating lease liabilities 31,991 33,259 Other liabilities 3,392 1,967 Total liabilities 371,052 352,675 Total stockholders’ equity (deficit) (861 ) (29,615 ) Total liabilities and stockholders’ equity (deficit) $ 370,191 $ 323,060 View source version on businesswire.com: https://www.businesswire.com/news/home/20251106200297/en/ Investor Contact Allison Wey Senior Vice President, Investor Relations and Corporate Communications awey@xerispharma.com Source: Xeris Biopharma Holdings, Inc.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Mr. Paul Edick to its Board of Directors (“Board”). Following the appointment of Mr. Edick, Vistagen’s Board will be comprised of seven directors. Mr. Edick will serve on the Audit Committee and the Compensation Committee of the Board. “We are pleased to welcome Mr. Edick to our Board of Directors,” said Maggie FitzPatrick, Chair of the Board. “Paul’s distinguished record of board and CEO leadership, deep industry expertise, and financial discipline will further strengthen our governance. His experience and strategic insight will be instrumental as we continue advancing innovative solutions for patients while working to deliver long-term value for shareholders.” “Paul joins our Board at a monumental moment for Vistagen, bringing extensive experience and leadership in the biopharmaceutical industry,” said President and Chief Executive Officer, Shawn Singh. “His proven ability to lead complex operational initiatives, across FDA approvals, public offerings, and acquisitions, will be pivotal as we prepare for our next phase of strategic growth. We want to extend our gratitude to Dr. Jerry Gin, who served on our Board beginning in 2016 until his retirement in September of this year.” Mr. Edick most recently served as the Chairman and Chief Executive Officer of Xeris Pharmaceuticals from January 2017 until his retirement in August 2024, when he moved into a senior advisory role with the company. Before Xeris, he was the Founding Partner of 3G Advisors, a consultancy to the pharmaceutical, healthcare, and healthcare investor communities. From 2010 to 2014, Mr. Edick was the Chief Executive Officer of Durata Therapeutics, which was acquired by Actavis PLC, now Allergan PLC. Prior to Durata, Mr. Edick led several pharmaceutical companies, including Ganic Pharmaceuticals and MedPointe Healthcare. He also has extensive board experience, having served on the boards of Milestone Pharmaceuticals, Iterum Therapeutics, Durata Therapeutics, PDL BioPharma, Neos Therapeutics, NewLink Genetics, Circassia Pharmaceuticals, Sucampo Pharmaceuticals, Life Cycle Pharma, Amerita, and Informed Medical Communications. “I am honored to join this talented and dynamic Board,” said Mr. Edick. “Vistagen has the opportunity to address many unmet mental health needs through its differentiated pipeline of product candidates, and I look forward to supporting the company through its next stage of growth.” About Vistagen Headquartered in South San Francisco, CA, Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to rapidly trigger olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. They are designed to achieve therapeutic benefits without requiring absorption into the blood or uptake into the brain, giving them the potential to be a safer alternative to other pharmacological options if successfully developed and approved. Vistagen is passionate about developing transformative treatment options to improve the lives of individuals underserved by the current standard of care for multiple highly prevalent indications, including social anxiety disorder, major depressive disorder, vasomotor symptoms (hot flashes) associated with menopause, and premenstrual dysphoric disorder. Connect at www.Vistagen.com. Forward-looking Statements This press release contains certain forward-looking statements within the meaning of the federal securities laws, including, without limitation, statements regarding Mr. Edick’s service on the Board and Board committees, and the potential attributes and benefits of Vistagen’s product candidates. These forward-looking statements involve known and unknown risks that are difficult to predict and include all matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “project,” “outlook,” “strategy,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “strive,” “goal,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by Vistagen and its management, are inherently uncertain. As with all pharmaceutical products, there are substantial risks and uncertainties in the process of development and commercialization and actual results or developments may differ materially from those projected or implied in these forward-looking statements. Risks that may impact the outcome of these forward-looking statements are more fully discussed in the section entitled “Risk Factors” in Vistagen’s Annual Report on Form 10-K for the fiscal year ended March 31, 2025, and Quarterly Report on Form 10-Q for the period ended June 30, 2025, as well as discussions of potential risks, uncertainties, and other important factors in Vistagen’s other filings with the U.S. Securities and Exchange Commission (“SEC”). Vistagen’s SEC filings are available on the SEC’s website at www.sec.gov. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing Vistagen’s views as of any subsequent date. Vistagen explicitly disclaims any obligation to update any forward-looking statements other than as may be required by law. If Vistagen does update one or more forward-looking statements, no inference should be made that Vistagen will make additional updates with respect to those or other forward-looking statements.